leisure time -WSS

leisure time

author：comprehensive 2025-10-01 02:13:29 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Kansas must stop changing trans people's sex listing on driver's licenses, judge says

WSS

The PBM ad wars are taking over Washington, D.C.

Bill would allow buprenorphine prescription for addiction via telehealth

Travis Kelce and the trap of celebrity vaccine endorsements

Bill would allow buprenorphine prescription for addiction via telehealth

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Readout LOUD podcast: ESMO highlights & Roivant's big deal

hotspot

leisure time

focus

At least 13 dead in Texas as scorching temps continue

Rare Northern Lights show in US this week: Where and how to see it

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Walensky prepares to leave CDC — and Congress — behind

Trump seeks lengthy delay of classified docs trial, citing upcoming election

ChatGPT in medicine: STAT answers readers' burning questions

How neuroscience research could help beat back brain cancer

Anesthesiologist group: stop taking Ozempic before surgery

With fresh data, a dynamic duo powers Eli Lilly to new heights

leisure time

How neuroscience research could help beat back brain cancer

After Sarepta trial failure, Duchenne families brace for more debate

Rare Northern Lights show in US this week: Where and how to see it

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

explore

hotspot

knowledge

hotspot